Aarti Drugs: CEO Prakash Patil retires; Adhish Patil named MD, Gogri becomes Chairman

CEO resignedPromoter family joins the boardKey managerial personnel resignedManagement Changes View source PDF Explain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹423.00

prior close

₹424.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%-5.0% vs market

Pharmaceuticals peers, median of 163sector+1.0%-4.6% vs sector

On the reaction day the stock moved 5.0 pts less than Nifty Microcap 250 and 4.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.7

10m

-3.0

15m

-2.7

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6+1.3-5.0+1.0-4.6

Next day

-2.4+1.8-4.1+0.8-3.2

-2.7+3.1-5.7+0.3-3.0

-2.8+3.5-6.3+0.7-3.6

-1.1+3.5-4.6+1.5-2.6

+0.0+3.4-3.4+1.3-1.3

+2.4+3.6-1.3+1.5+0.9

15d

-0.1+4.9-4.9+0.9-1.0

+0.5+4.4-3.9+1.7-1.2

-2.0+2.9-4.9+1.9-3.9

+10.3-3.5+13.8-3.1+13.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Drugs' Chairman, MD and CEO Prakash M. Patil will retire from September 30, 2026, ahead of his scheduled May 2027 term end, citing an orderly leadership transition. Existing MD Rashesh C. Gogri (promoter group) will add Chairman role from October 1, 2026. CFO Adhish P. Patil, son of the outgoing Chairman, will be elevated to MD for 5 years. Uday M. Patil retires after 25 plus years. Board committees are reconstituted.

Likely market impact

Pre-planned transition with promoter family succession; Adhish Patil as new MD, Gogri as Chairman. Subject to shareholder approval at next AGM.